Filing Flows › Comparisons › LGVN vs CPMD
Longeveron vs Cannapharmarx: LGVN and CPMD compared
Longeveron is the larger company: $287K of revenue in its latest quarter (Q2 2026) against $276K for Cannapharmarx (Q2 2026). Cannapharmarx is growing faster (+19% against -9% a year earlier).
Where the money goes: LGVN and CPMD
Longeveron (LGVN) · Q2 2026
Longeveron, Q2 2026: revenue $287K (-9% year over year), net loss $6.1M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
Cannapharmarx (CPMD) · Q2 2026
Cannapharmarx, Q2 2026: revenue $276K (+19% year over year), operating margin -137.1%, net loss $1.9M, operating cash flow −$127K. The chart follows the revenue to costs, profit and cash.
| Longeveron (LGVN) | Cannapharmarx (CPMD) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $287K | $276K |
| Revenue growth, Y/Y | -9% | +19% |
| Operating margin | n/m | -137.1% |
| Net earnings | −$6.1M | −$1.9M |
| Net margin | — | -691.1% |
| Operating cash flow | −$5.7M | −$127K |
Questions
Which is bigger, Longeveron or Cannapharmarx?
Longeveron is the larger company: $287K of revenue in its latest quarter (Q2 2026) against $276K for Cannapharmarx (Q2 2026).
Is Longeveron or Cannapharmarx growing faster?
Cannapharmarx is growing faster (+19% against -9% a year earlier).
More: Longeveron earnings · how Longeveron makes money · Cannapharmarx earnings · how Cannapharmarx makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 18, 2026). Fiscal quarters can end on different dates. Not investment advice.